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Abstract To assess the cost-effectiveness of abatacept
compared to different biologic treatment strategies for
moderate to severe rheumatoid arthritis based on current
medical practices in Canada. A model was constructed to
assess the cost-effectiveness of various biologic treatments
over a 2-year time horizon, using two effectiveness
endpoints: “low disease activity state” (LDAS) and “remis-
sion”. Abatacept, as first biologic agent after an inadequate
response to DMARDs, provides greater treatment success
rate for achieving LDAS (29.4% versus 15.6%) and
remission (14.8% versus 5.2%), and appears significantly
more cost-effective compared to the sequential use of anti-
TNF agents (p<0.001). Abatacept, as second biologic agent
after an inadequate response to one anti-TNF agent,
provides greater treatment success rate for achieving LDAS
(17.1% versus 10.2%) and remission (7.4% versus 3.9%)
and appears significantly more cost-effective compared to
the sequential use of anti-TNF agents (p<0.001). Abatacept
is a cost-effective strategy in patients with an inadequate
response to DMARDs or to one anti-TNF agent.
Keywords Abatacept . Anti-TNF therapy . Cost-
effectiveness .Modeling . Rheumatoid Arthritis
Introduction
During the past decade, the therapeutic management of
patients with Rheumatoid Arthritis (RA) has undergone sig-
nificant evolution. There has been a shift in the management
of RA towards beginning therapy immediately with disease-
modifying anti-rheumatic drugs (DMARDs) in order to
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control disease activity, to reduce functional impairment and
to prevent irreversible changes in cartilage and bone [1].
However, in the long term, patients treated with DMARDs
may show deterioration in radiographs and joint function,
indicating the need for improved therapies. To address these
unmet needs, biologic agents were developed and provide
treatment alternatives for patients with an inadequate
response to DMARDs. The first biologic agents introduced
on the market were tumor necrosis factor antagonists (anti-
TNFs) and include etanercept, infliximab, and adalimumab.
Although anti-TNF therapies combined with methotrex-
ate (MTX) have shown improved efficacy in clinical trials
compared to DMARDs alone, a significant proportion of
patients are not effectively treated with these biologic
therapies, either due to lack or loss of efficacy and/or to
adverse events. In controlled clinical trials, 25% to 50% of
patients fail to achieve the minimum 20% improvement in
ACR criteria following anti-TNF treatment, and only a
small proportion of patients achieves a 50 or 70%
improvement [2–7]. In addition, some studies have shown
that treatment discontinuation rates with anti-TNF treatment
approaches 30% at 1 year, due to lack or loss of efficacy
and/or to adverse events [8, 9]. There is also emerging
evidence of a risk of decreased efficacy with the sequential
use of anti-TNF therapies [8]. For these patients, this
represents an unmet medical need for which new therapeu-
tic options are required. Furthermore, direct and indirect
medical costs associated with RA are significant [10]. Thus,
alternative treatment strategies have been developed to
address the above unmet needs [11, 12].
To assist decision-making, the introduction of a new
biologic option, such as abatacept, requires an assessment
of its value in the context of existing therapies. The value of
a new therapeutic option is defined by its clinical benefits
and by conducting cost-effectiveness analyses which assess
and compare the effectiveness of different technologies in
relation with their corresponding overall treatment costs.
The arrival of abatacept, the first of a new class of
biologic agents for rheumatoid arthritis known as selective
co-stimulation modulators, offers a new therapeutic alter-
native for patients with moderate to severe active RA and
an inadequate response to one or more DMARDs and/or to
TNF antagonists [11, 12].
Materials and methods
Model framework
In the absence of well-designed head-to-head clinical trials
assessing and comparing the effectiveness of various biologic
agents, economic evaluations of health care technologies use
models to synthesize evidence from multiple sources in order
to estimate short, mid-, or long-term costs relative to the
outcomes of various therapeutic strategies. These models
allow the representation of current treatment patterns, thera-
peutic strategies, and treatment switches, and take into
account the overall impact of both treatment success and
failure relative to each technology being assessed [13].
The objective of this simulation model was to assess the
cost-effectiveness of abatacept vs. anti-TNF therapies in
patients with moderate to severe RA and with an inadequate
response to one or more DMARDs and/or anti-TNF agents.
The analysis includes direct costs and was thus conducted
using the perspective of the public payer.
The defined population entering this model is composed of
patients with moderate to severe RA with an inadequate
response to DMARDs, eligible for biologic therapy. In this
model, patients achieving treatment success (defined as either
achieving a low disease-activity state (LDAS) or remission)
are maintained on existing therapy for up to 2 years. Only
those with an inadequate response to a biologic therapy are
switched to a subsequent biologic agent, with decision to
switch made at 6 months intervals in case of an inadequate
response. To assess the cost-effectiveness of abatacept used as
first biologic therapy in patients with an inadequate response
to DMARDs and as second biologic therapy in patients with
an inadequate response to a first anti-TNF agent, the
comparator was defined as a successive trial of anti-TNF
therapies based on the most established treatment pattern in
Canada at time of model development. The selection of
treatment options was based on local medical practices and the
most robust drug prescription surveys available. As rituximab
was not reimbursed for rheumatoid arthritis in Canada at time
of model development, it was not considered a valid
comparator for the purpose of this analysis.
In this model, each strategy being assessed and compared
is composed of different biologic agents used successively
following an inadequate response to the previous treatment.
The model also includes two clinically relevant effectiveness
endpoints (either achieving LDAS or remission), which are
defined as the most desirable and clinically relevant out-
comes in RA [14–16]. To take into account all potential
therapeutic scenarios and clinical outcomes, 14 decision
trees similar to the one presented in Fig. 1 were developed.
The decision tree illustrated in Fig. 1 is composed of 45
health states (branches) and 30 transition probabilities. Each
decision tree uses the following set of parameters: Success
rate (LDAS or remission rate) over 2 years and confidence
interval (CI), Corresponding medical costs over 2 years and
CI, Mean cost-effectiveness ratios (mean costs divided by
mean effectiveness) and CI, and Incremental cost-effective-
ness ratios (ICER: costs difference divided by effectiveness
difference) of one strategy versus an alternative strategy.
These decision trees were designed as “simulation
models” and programmed to take into account the entire
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distribution costs and distribution effectiveness for each
pre-defined parameter according to specific distribution
laws. For simulation models consuming large amounts of
computer processing time, powerful workstations with
parallel-processors and adapted programming languages
(Dscript language—DecisionPro® software) were used.
Other model assumptions were considered consistent
with clinical practices: the same treatment continues as long
as it is efficacious; decision to switch treatment may occur
only in case of lack of success to treatment for all causes
(e.g., lack or loss of efficacy, adverse events, intolerance,
etc); the model allows switches to occur every 6 months.
Regarding costing aspects, this cost-effectiveness analy-
sis uses the perspective of the public payer and considers
direct medical costs. However, given the significant indirect
costs associated with RA, the cost-effectiveness results can
be considered conservative from a societal perspective.
Effectiveness endpoints
The primary objective when treating RA is to control
inflammatory activity of the disease, and if possible, to
achieve remission [14–16]. Thus, clinical remission is
considered as the most desirable clinical outcome [14].
Control of disease activity in RA is therefore an important
treatment goal for preventing the progression of joint damage
and functional disability, and their clinical and economic
consequences [17, 18]. Remission has been most often
defined using the Disease-Activity Score (DAS) which is a
composite index that includes variables such as the number
of tender and swollen joints, erythrocyte sedimentation rate
(ESR), and the patient’s assessment of disease activity. This
index facilitates the quantification of disease activity and
provides a more reliable overall estimate than would each
individual measurement [16]. While the original DAS44
score is based on the assessment of 44 joints, a DAS index
using a low number of joint counts (DAS28) was developed
and validated and the response criteria appear to be as valid
as the ones with larger number of joint counts. Hence for
simplicity, the reduced number of joint counts (DAS28) is
now preferred in standard clinical practice [16]. Newer and
simpler indices are also gaining in acceptance such as the
Simple Disease-Activity Index (SDAI) and the Clinical
Disease-Activity Index (CDAI).
Given that remission and LDAS represent the primary
treatment objectives in RA, for the purpose of this cost-
effectiveness analysis, treatment effectiveness was defined
as either achieving disease remission (DAS28<2.6) or
LDAS (DAS28≤3.2).
The DAS induction data used to populate the model are
from published pivotal trials and the maintenance data (up to
2 years) are from either published trials or clinical trial
analyses [11, 12, 19, 20]. For abatacept, clinical trial
evidence included all clinical evidence available and
published at time of model development. This included
12 months data in patients with an inadequate response to
DMARDs (Phase II and Phase III AIM trial) [12, 20] and
6 months data in patients with an inadequate response to
anti-TNF therapies (ATTAIN trial) [11]. Two-year extension
maintenance effectiveness data from both pivotal trials was
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Fig. 1 Decision tree framework—abatacept used as first biologic option over 2 years (success endpoint: remission)
Clin Rheumatol (2009) 28:403–412 405
used confirming long-term and sustained clinical benefits in
both patient populations responding adequately [21, 22].
The safety of abatacept in patients with RA was
evaluated in a large, randomized, placebo-controlled trial
[23] and in the ATTAIN and AIM trials and extension
studies [21, 22].
As indicated in Table 1, the induction effectiveness data
(effectiveness of one specific biologic class appearing in the
sequence for the first time) is from the etanercept [19] and
from the abatacept clinical trials available at time of model
development [11, 12, 20].
The maintenance effectiveness data beyond the first 6-
month cycle (i.e., effectiveness of one specific biologic
class maintained after the first cycle and for one or more
subsequent 6 months cycles) in DMARDS inadequate
responders is again from the TEMPO trial for etanercept
and from the AIM trial for abatacept. Considering the
TEMPO trial [19], effectiveness data comes from the third
arm of the trial combining etanercept and methotrexate.
This is consistent with the effectiveness data extracted from
the abatacept trials (AIM and ATTAIN) where abatacept
was used in combination with DMARDs.
The maintenance effectiveness data in anti-TNF inade-
quate responders is from the ATTAIN trial for abatacept
[11]. In the absence of well-designed controlled clinical
trials assessing the effectiveness of anti-TNFs in anti-TNF
inadequate responders, the ATTAIN study results were
objectively applied to each anti-TNF switch, using the
assumption of a 10% reduction in effectiveness after each
switch. This assumption reflects the unanimous opinion of
the clinical experts as well as recent clinical evidence
reporting that switching anti-TNF agents is often associated
with a lower efficacy and/or increased rate of treatment
discontinuation [8, 24–27].
As economic modeling considers active treatment arms,
placebo adjustment was not performed. This is because
the objective of most cost-effectiveness models is to
consider “effectiveness” data (total observed effectiveness
including placebo effect, concomitant drugs effects such
as MTX, etc.), and not only “efficacy” data (effect of one
active agent considered in isolation) in order to reflect
real-life settings. However, the proposed methodology
does take into account study population variability (differ-
ences in inclusion and exclusion criteria, protocols, etc.) in
simulating all parameters distributions (extensive probabi-
listic sensitivity analysis using Monte Carlo simulation
techniques).
The model calculates as an effectiveness outcome the
overall effectiveness of each entire sequence of biologic
strategies. The final outcome of the model is a computation
and comparison of different sequences of biologic strategies
to reflect current medical practice, which consists of
switching biologic therapies in case of an inadequate
response to the previous one.
Cost analysis
Drug costs are expressed in Canadian dollars and were
calculated based on approved product monographs in
Canada and 2006 list prices (Table 2). Where relevant, the
number of units required per year was calculated based on
the average body weight in Canada estimated at 75 kg for
the targeted age group of 45–64 years [28].
As per approved label, abatacept is administered over a
30-min i.v. infusion (no pre-medication required) at 2 and
4 weeks after the first infusion, and every 4 weeks
thereafter. Assuming a 75 kg average body weight in
Canada and based on abatacept fixed dose regimen per
body weight range (<60 kg=500 mg, ≥60 and ≤100 kg=
750 mg, and >100 kg=1,000 mg) [Health Canada Product
Monograph 2006], the analysis considers an average dose
Table 2 Estimated annual costs of therapy
Estimated annual cost of
biological therapiesa
Year 1 (CAN $) Year 2 (CAN $)
Abatacept (250 mg vial)b,c $18,480 $17,160
Adalimumab (40 mg pre-filled
syringe)
$17,680 $17,680
Etanercept (25 mg vial) $18,200 $18,200
Infliximab (100 mg vial)b,c,d $20,445 $18,330
Based on Health Canada product monographs and published literature
a Reported on a 6-month basis in the cost-effectiveness model
b Assuming an average body weight of 75 kg
c Includes loading dose Year 1
d Assuming 3 mg/kg for the first three doses (at week 0, 2, and 6) then
an average of 4 mg/kg every 8 weeks thereafter (i.e., 50% of patients
requiring 3 mg/kg and 50% requiring 5 mg/kg)
Table 1 Induction success
rates (% patients achieving low
disease-activity state and
remission)
Biologic therapy Low disease-activity state Remission Source
Abatacept (DMARD inadequate
responders)
0.40 0.261 Kremer 2005
Abatacept (anti-TNF inadequate
responders)
0.183 0.111 ATTAIN Study
Etanercept (DMARD inadequate
responders)
0.45 0.303 TEMPO Study
(van der Heijde 2006)
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of 750 mg (3×250 mg vials) per infusion. Infusion costs
were not included because in Canada, infliximab and
abatacept were administered in participating rheumatology
and infusion clinics (and even at home for abatacept) and
hence, were not incurred by the public payer.
Direct medical costs per DAS score categories were
assessed based on a Canadian cost survey [29, 30]. In this
study, data were collected from 253 adult patients throughout
the province of Ontario. Detailed resource utilization items
of the following cost categories were collected: visits to
health professionals [family physician, specialist (non-surgi-
cal reported separately from surgical visits), allied health,
dentist], laboratory tests or investigation (X-ray, CT, MRI,
ultrasound, ECG, other laboratory, bone density), hospital-
izations, prescribed drugs (arthritis [not including anti-TNF
or co-stimulation modulator], anti-hypertensive, gastro-pro-
tective, other), home care, transportation services. adaptive
aids/other devices.
Direct medical cost data were analyzed for 138 patients
for whom four DAS components were complete. Data for
these RA patients were tabulated and categorized within the
DAS framework by threshold scores (Table 3) [29].
Uncertainty management
For each uncertain variable (one that has a range of possible
values), probability distribution and confidence intervals
were selected by the authors. A lognormal distribution
shape was selected to program costing variability. The main
advantage of lognormal distribution is the zero origin,
which allows the simulation of costing data.
A beta distribution shape was selected to program
transition probabilities variability. Beta distribution is a
continuous probability distribution with the function de-
fined on the interval [0, 1], which allows to simulate
probability data (always between 0 and 1=100%). For
example, as different studies were used to provide the
efficacy data in the model, one could argue that patient
populations would not be similar and consequently,
treatment responses would not be directly comparable.
Taking into account the entire distribution of effectiveness
parameters, this potential variability was addressed and
managed by the model.
In addition, as recommended in the 2006 Canadian
Agency for Drugs and Technologies in Health (CADTH)
guidelines for economic evaluation of health technologies
(www.cadth.ca), an extensive probabilistic sensitivity analysis
using Monte Carlo simulations was used to manage the
uncertainty of the model. Monte Carlo simulations randomly
select a value from the defined possibilities (range and shape
of the distribution) of each parameter and then recalculates
the outcomes [31]. Confidence intervals of outcomes have
been calculated using 5,000 Monte Carlo simulations. By
screening all uncertain parameter values to construct
outcome confidence intervals, this approach is considered
a robust sensitivity analysis (“probabilistic sensitivity
analysis”) [31–34].
Results
Reference case: 2-year treatment with up to three
successive biologic agents (in case of an inadequate
response to the previous biologic agent)
Achieving LDAS after an inadequate response to DMARDs
Considering the current anti-TNF sequential strategy of
reference:
– Etanercept→ Infliximab→Adalimumab→DMARDs
the following therapeutic strategies including abatacept
were simulated:
– Abatacept → Etanercept → Infliximab→ DMARDs
– Etanercept→ Abatacept→ Infliximab→ DMARDs.
Considering patients with an inadequate response to
DMARDs entering the model, compared to anti-TNF
therapies, the lowest cost biologic strategy was abatacept
used as the first biologic agent. This strategy was dominant
(i.e., both more effective and less costly), providing 13.8%
greater probability of achieving LDAS than sequential anti-
TNF therapy (29.4% vs. 15.6%) with an overall RA-related
cost-saving of $730 ($39,759 vs. $ 40,489) over 2 years
(Table 4).
Using the same patient population at entry, abatacept
used as second biologic after an inadequate response to
one anti-TNF agent (etanercept) was compared to sequen-
tial anti-TNF therapies. Abatacept was cost-effective,
providing 3.7% greater probability of achieving LDAS
(19.3% vs. 15.6%) at an additional cost of $463 ($40,952
vs. $40,489) over the 2-year period, representing an incre-
Table 3 Total 6-month direct costs per DAS categories
DAS category Number of patients Direct 6 months costs
(CAN$)
Mean s.d.
DAS≤2.6 4 1,052 235
DAS>2.6 134 1,994 1,352
DAS≤3.2 11 1,764 2,069
DAS>3.2 127 1,984 1,271
W Katchamart, X Li, C Bombardier, Direct and Indirect Costs of
Rheumatoid Arthritis are Strongly Correlated with Disease Activity
and Functional Status, 2006 ACR/ARHP Poster Session B
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mental cost-effectiveness ratio (ICER) of $12,514 per
additional case of LDAS gained (Table 4). Thus, abatacept
used as first biologic appears to be less costly and to
provide greater probability of achieving LDAS than using
abatacept as second biologic agent. Mean cost-effective-
ness ratio also showed statistically significant lower cost
for achieving LDAS with abatacept as first biologic agent
(p<0.0001).
Achieving remission after an inadequate response
to DMARDs
Using the sequential biologic strategies cited above, the
same simulations were conducted with disease remission as
the effectiveness endpoint. Again, the lowest cost strategy
was abatacept used as the first biologic agent (Table 4).
This strategy was dominant, providing 9.6% greater
probability of remission compared to sequential anti-TNF
therapy (14.8% vs. 5.2%) with an overall RA-related cost-
saving of $504 ($38,061 vs. $ 38,565). Using the same
population of patients with an inadequate response to
DMARDs at entry, abatacept used as second biologic after
inadequate response to one anti-TNF agent (etanercept) was
compared to sequential anti-TNF therapies. Abatacept was
cost-effective, providing 3.5% greater probability of remis-
sion (8.7% vs. 5.2%) at an additional cost of $589 ($39,154
vs. $38,565) over the 2-year period, representing an
incremental cost-effectiveness ratio (ICER) of $16,829 per
additional remission gained. Again, abatacept used as first
biologic was found to be less costly overall and to provide
greater probability of remission than abatacept used as
second biologic option (Table 4).
Mean cost-effectiveness ratio also showed statistically
significant lower cost for achieving remission with abata-
cept used as first biologic agent (p<0.0001).
Achieving LDAS or remission after an inadequate response
to one anti-TNF agent
To assess the cost-effectiveness of abatacept in patients
with an inadequate response to one anti-TNF agent,
alternate modeling was performed where this time the
model only enrolled patients with an inadequate response to
a first anti-TNF agent (etanercept). This alternate model
was conducted to allow a more direct comparison of
abatacept as second biologic agent versus sequential anti-
TNF therapies in this patient population. The model was
programmed setting a failure to an initial 6-month treatment
with etanercept so that all patients were switched to either
abatacept or infliximab as the second biologic option,
followed by infliximab and adalimumab, respectively.
Under this alternate modeling approach, compared to
cycled anti-TNF therapies, abatacept used as second
biologic agent after an inadequate response to one anti-
TNF agent was cost-effective, providing 6.9% additional
treatment success rate for achieving LDAS (17.1% vs.
10.2%—Table 5) and 3.5% additional treatment success
rates for achieving remission (7.4% vs. 3.9%—Table 5), at
an incremental cost-effectiveness ratio (ICER) of $20,377
per additional case of LDAS and $26,400 per additional
remission, respectively.
Discussion
When conducting economic evaluations, it is recommended
to use data analogous to real-life benefits and a clinical
pathway consistent with the practice of the country in
which the analysis is conducted [33]. Economic evaluations
should also reflect clinical practice and ideally, should
include disease-specific clinical outcomes [34].
Table 4 Cost-effectiveness of
abatacept vs. anti-TNF strate-
gies for achieving low disease-
activity state and remission in
patients with an inadequate
response to DMARDs
Sequential biologic strategies Treatment
Cost (2 years)
Treatment
success
Mean cost-
effectiveness
p value ICER
Low disease-activity state
Abatacept–etanercept–
infliximab–DMARDs
$39,759 0.294 $136,730 <0.0001 Dominant
Etanercept–abatacept–
infliximab–DMARDs
$40,952 0.193 $213,872 <0.0001 $12,514
Etanercept–infliximab–
adalimumab–DMARDs
$40,489 0.156 $261,943 – –
Remission
Abatacept–etanercept–
infliximab–DMARDs
$38,061 0.148 $263,240 <0.0001 Dominant
Etanercept–abatacept–
infliximab–DMARDs
$39,154 0.087 $463,689 <0.0001 $16,829
Etanercept–infliximab–
adalimumab-DMARDs
$38,565 0.052 $795,920 – –
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As achieving LDAS or remission represent primary
therapeutic objectives and most desirable clinical outcomes
in RA [14–16], achieving these treatment outcomes is
becoming an important measure by which to compare
different treatment strategies [35].
Since response relative to baseline may have less
significance as duration of a particular therapy increases,
describing the disease status in absolute terms may be more
relevant in this circumstance. As suggested by the Outcome
Measures in Rheumatology Clinical Trials (OMERACT)
group, this can be done by a continuous absolute measure
such as the DAS and by counting the proportion of patients
classified as being in remission or in a low disease-activity
state [34]. Thus, achieving LDAS or remission was used as
the most clinically relevant effectiveness endpoints in this
analysis. The OMERACT group also suggests that com-
parative studies in RA consider not one therapeutic agent
but rather a sequence of therapies over the long term, i.e., a
therapeutic sequence strategy. Modeling of therapeutic
sequences is of particular importance in evaluating the
cost-effectiveness of a chronic disease therapy to help
identify the most clinically relevant population for a new
drug, and where it may be best positioned within an
established therapeutic sequence [34]. While realistic
sequences should be modeled, depending on the clinical
setting, research documenting the type of sequences used
by rheumatologists is also lacking.
Comparing across clinical trials is always a difficult task
as populations and methodologies are not necessarily
similar. This is why such approaches must be undertaken
with extreme caution. However, robust meta-analyses are
nowadays considered as part of evidence-based medicine
and simulation models provide interesting additional
techniques to combine and compare data from different
sources (clinical trials, literature, reports, observational
data, etc.). In the present model, data variability was
managed using probabilistic sensitivity analyses and vali-
dated assumptions to integrate data from heterogeneous
sources. Hence, modeling approaches provide methodolog-
ical frameworks for conclusions to be interpreted in the
context of their specific underlying assumptions.
For the purpose of this cost-effectiveness analysis
(CEA), in the absence of comparative trials, the most
established anti-TNF treatment pattern in Canada at time of
model development was used as comparator, based on local
medical practice and market research data, and validated by
an expert panel six expert rheumatologists.
Clinical trials duration represents another challenge
when assessing long-term impact. Most experts agree that
models should include at least one-year time horizon as
modeling clinical benefit beyond trial duration is a
contentious element that often requires relative outcomes
measures which may impede the comparability of economic
evaluations [33, 34]. To best reflect clinical practice in this
model, in accordance with clinical experts, the time horizon
was set at 2 years with the possibility to switch treatment at
6-month intervals in case of inadequate response.
Another type of economic evaluation to consider could
have been to conduct a cost-utility analysis (CUA) which
requires the use of “utility” scores (preference assessment)
to generate Quality Adjusted Life Years (QALY) as a
potential composite assessment indicator. These type of
economic evaluations are regularly published in the area of
rheumatology [36–38] but are often inadequately presented
as “cost-effectiveness” studies. This may add to the
confusion regarding two methods that are neither equivalent
nor interchangeable. While real cost-effectiveness analyses
compare costs with an effectiveness criteria expressed in
natural unit of clinical outcome (such as “disease remis-
sion” as a valid clinical success criteria), cost-utility
analyses compare costs with a QALY indicator derived
from patient preferences to construct a “utility” score.
However, there is increasing evidence that the QALY
indicator used in RA may lead to divergent or inconsistent
results depending on the utility assessment method used
[33, 39–44]. As reported in the CADTH economic guide-
lines, CUAs and related preferences assessment instruments
often produce different scores for the same health state.
Table 5 Cost-effectiveness of
abatacept vs. anti-TNF strate-
gies for achieving low disease-
activity state and remission in
patients with an inadequate
response to one anti-TNF
Sequential biologic strategies Treatment cost
(2 years)
Treatment
success
Mean cost-
effectiveness
p value ICER
Low disease-activity state
Etanercept–abatacept–
infliximab–DMARDs
$38,596 0.171 $231,654 <0.0001 $20,377
Etanercept–infliximab–
adalimumab-DMARDs
$37,190 0.102 $389,999 –
Remission
Etanercept–abatacept–
infliximab–DMARDs
$37,281 0.074 $541,925 <0.0001 $26,400
Etanercept–infliximab–
adalimumab–DMARDs
$36,357 0.039 $1,131,085 – –
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Another reported concern is that the QALY is not a
clinically meaningful indicator and may not discriminate
between conditions with different severity. Furthermore,
most cost-utility models expressed in cost/QALY use a
long-term time horizon [such as lifetime in the Brennan
model [38] and very fragile assumptions regarding long-
term efficacy. Given these limitations, a CEA was preferred
for the purpose of this analysis where results are presented
in terms of costs per unit of clinical effectiveness expressed
in natural outcome units over a 2-year time horizon,
consistent with clinical trials evidence, and without having
to speculate nor to project non-evidence-based long-term
efficacy over lifetime.
However, improvement in quality of life is of paramount
importance in the management of RA and using a real cost-
effectiveness demonstration (expressed in cost per clinical
outcome) should not reduce the significance of the
improvement in quality of life as an important and relevant
additional outcome. When compared to traditional
DMARDs, abatacept was shown in the AIM and ATTAIN
trials to statistically significantly improve all quality of life
domains in patients with an inadequate response to
DMARDs and/or to anti-TNF therapy [11, 12].
Clinical guidelines currently recommend the use of
biologic agents after an inadequate response to traditional
DMARDs. Abatacept introduces a new class of biologic
agents with a distinct mechanism of action than anti-TNF
agents. Incremental clinical and economic value is therefore
expected given the risk of reduced efficacy and high
discontinuation rates reported with the sequential use of
anti-TNF therapies [8, 24–27], and the well-reported issue
of dose escalation with infliximab in more than 50% of
patients [45–51].
The uniqueness and strength of this cost-effectiveness
analysis is that it uses robust and clinically relevant
outcomes as effectiveness endpoints (i.e., remission or
LDAS as RA treatment goals) to compare therapeutic
strategies which represent current medical practice for the
management of RA, including biologic treatment switches.
Conclusion
This advanced cost-effectiveness modeling is the first
assessing various biologic strategies based on current
medical practice for the management of RA in Canada.
The results show that when used as first biologic agent in
patients with moderate to severe RA and with an
inadequate response to DMARDs, abatacept appears to be
dominant (i.e., overall less costly and more effective)
compared to anti-TNF therapies, consistently showing
significantly lower treatment cost and better probability of
achieving treatment success, defined as either LDAS or
remission. The results also show that when used as second
biologic agent in patients with an inadequate response to a
first anti-TNF agent, abatacept is cost-effective compared to
anti-TNF therapies. This CEA being based on direct costs,
the cost-effectiveness results are likely understated from a
societal perspective. Once comparative long-term clinical
evidence becomes available, similar modeling approaches
will be useful to simulate long-term costs, effectiveness,
and cost-effectiveness.
Acknowledgment We are grateful to Dr Claire Bombardier, MD,
FRCPC, Mount Sinai Hospital, University of Toronto (Canada) for
providing the data on the Ontario cohort for the calculation of the cost
per DAS categories.
Disclosures Anthony Russell, Ariel Beresniak, Louis Bessette,
Boulos Haraoui, Proton Rahman and Carter Thorne have received
fees and honorarium to attend Steering Committee meetings and to
defray travel expenses reimbursement from Bristol-Myers Squibb.
Ross Maclean and Danielle Dupont are employees of Bristol-Myers
Squibb.
Source of funding The work has been sponsored by Bristol-Myers
Squibb International.
References
1. Pisetsky D, St Clair E (2001) Progress in the treatment of
rheumatoid arthritis. JAMA 286:2787–2790
2. Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R,
Fox R, Jackson C, Lange M, Burge D (1999) A trial of etanercept,
a recombinant tumor necrosis factor receptor: Fc fusion protein, in
patients with rheumatoid arthritis receiving methotrexate. N Engl J
Med 340:253–259
3. Weinblatt M, Keystone E, Furst D,Moreland L,WeismanM, Birbara
C, Teoh L, Fischkoff S, Chartash E (2003) Adalimumab, a fully
human anti-tumor necrosis factor alpha monoclonal antibody, for the
treatment of rheumatoid arthritis in patients taking concomitant
methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45
4. Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F,
Kalden J, Smolen J, Weisman M, Emery P, Feldmann M, Harriman
G, Maini R, Group A-TNFTiRAwCTS (2000) Infliximab and
methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor
Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy Study Group. N Engl J Med 343:1594–1602
5. Redlich K, Schett G, Steiner G, Hayer S, Wagner EJSS (2003)
Rheumatoid arthritis therapy after tumor necrosis factor and
interleukin-1 blockade. Arthritis Rheum 48:3308–3319
6. Klinkhoff A (2004) Biological agents for rheumatoid arthritis:
targeting both physical function and structural damage. Drugs
64:1267–1283
7. Smolen J, Steiner G (2003) Therapeutic strategies for rheumatoid
arthritis. Nature Reviews 2
8. Hyrich K, Lunt M, Watson K, Symmons D, Silman A (2007)
Outcomes after switching from one anti-tumor necrosis factor
agent to a second anti-tumor necrosis factor agent in patients with
rheumatoid arthritis. Arthritis Rheum 56:13–20
9. Flendrie M, Creemers M, Welsing PMJ, den Broeder AA, van
Riel PLCM (2003) Survival during treatment with tumour
410 Clin Rheumatol (2009) 28:403–412
necrosis factor blocking agents in rheumatoid arthritis. Ann
Rheum Dis 62:30–33
10. Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of
rheumatoid arthritis: an international long-term view. Semin
Arthritis Rheum 29:305–320
11. Genovese M, Becker J, Schiff M, Luggen M, Sherrer Y, Kremer J,
Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R,
Hagerty D, Dougados M (2005) Abatacept for rheumatoid arthritis
refractory to tumor necrosis factor alpha inhibition. N Engl J Med
353:1114–1123
12. Kremer J, Genant H, Moreland L, Russel A et al (2006) Effects of
abatacept in patients with methotrexate-resistant active rheumatoid
arthritis: a randomized trial. Ann Intern Med 144:865–876
13. Stahl J (2008) Modelling methods for pharmacoeconomics and
health technology assessment, an overview and guide. Pharma-
coeconomics 26:131–148
14. Makinen H, Kautiainen H, Hannonen P, Tuulikki S (2005)
Frequency of remissions in early rheumatoid arthritis defined by
3 sets of criteria. A 5-year followup study. J Rheumatol 32:796–
800
15. American College of Rheumatology (2002) Guidelines for the
management of rheumatoid arthritis. Arthritis Rheum 46:328–
346
16. Fransen J, Van Riel PLCM (2005) The disease activity score and
the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99
17. Welsing PMJ, van Gestel AM, Swinkels HL, Keimeney LALM,
Van Riel PLCM (2001) The relationship between disease activity,
joint destruction and functional capacity over the course of
rheumatoid arthritis. Arthritis Rheum 44:2009–2017
18. Welsing PMJ, Severens JL, Hartman M, van Gestel AM, van Riel
PLCM, Laan RFJM (2006) The initial validation of a Markov
model for the economic evaluation of (new) treatments for
rheumatoid arthritis. Pharmacoeconomics 24:1011–1020
19. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu
C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J,
Pedersen R, Fatenejad S, Investigators ftTS (2006) Comparison of
etanercept and methotrexate, alone and combined, in the treatment
of rheumatoid arthritis two-year clinical and radiographic results
from the TEMPO study, a double-blind, randomized trial. Arthritis
Rheum 54:1063–1074
20. Kremer J, Dougados M, Emery P, Durez P, Sibilia J, Shergy W,
Steinfeld S, Tindall E, Becker J, Li T, Nuamah I, Aranda R,
Moreland L (2005) Treatment of rheumatoid arthritis with the
selective costimulation modulator abatacept—12 month results of
a phase II double-blind, randomized, placebo-controlled trial.
Arthritis Rheum 52:2263–2271 Aug
21. Genovese M, Schiff M, Luggen M, Becker J, Aranda R, Teng J,
Li T, Schmidely N, Le Bars M, Dougados M (2007) Efficacy and
safety of the selective co-stimulation modulator abatacept follow-
ing 2 years of treatment in patients with rheumatoid arthritis and
an inadequate response to anti-TNF therapy. Ann Rheum Dis
(online) Oct 5:doi:10.1136/ard.2007.074773
22. Hervey P, Keam S (2006) Abatacept. Biodrugs 20:53–61
23. Weinblatt M, Combe B, Covucci A, Aranda R, Becker J,
Keystone E (2006) Safety of the selective costimulation modula-
tor abatacept in rheumatoid arthritis patients receiving background
biologic and nonbiologic disease-modifying antirheumatic drugs.
A one year randomized placebo-controlled study. Arthritis Rheum
54:2807–2816
24. Haraoui B, Cameron L, L’Archevêque J, Ouellet M, Choquette D,
Raynauld J (2007) Clinical response to a second or third anti-TNF
agent after discontinuation of the first. Implications for therapeutic
decision-making. 4th Canadian Association for Population Ther-
apeutics (CAPT) Congress Halifax
25. Navaro F, Marsal S, Gomez-Reino J, Perez-Pampon E (2006)
EULAR response and drug survival in clinical practice in RA
patients treated with anti-TNF therapy: results of an observational,
prospective, cohort study in Spain. Ann Rheum Dis 65:333
26. Van Vollenhoven R, Cullinane Carli C, Bratt J, Klareskog L
(2006) Six-year report of the STURE registry for biologicals in
rheumatology: satisfactory overall results, but plenty of room for
improvement. Ann Rheum Dis 65:511
27. Gomez-Reino J, Carmona L, Group tB (2006) Switching TNF
antagonists in patients with chronic arthritis: an observational
study of 488 patients over a four-year period. Arthritis Research &
Therapy 8:(doi:10.1186/ar1881); http://arthritis-research.com/con
tent/1188/1181/R1129
28. Canadian Fitness and Lifestyle Research Institute (1995) Physical
Activity Monitor. http://wwwdflrica/cflri/pa/surveys/95survey/
95surveyhtml
29. Katchamart W, Li X, Bombardier C (2006) Direct and indirect
costs of rheumatoid arthritis are strongly correlated with disease
activity and functional status. ACR/ARHP 625
30. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C
(2004) The economic burden associated with osteoarthritis,
rheumatoid arthritis and hypertension: a comparative study. Ann
Rheum Dis 63:395–401
31. Welsing PMJ, Severens JL, Harman M, van Riel PLCM, Laan
RFJM (2004) Modeling the 5-year cost-effectiveness of treatment
strategies including tumor necrosis factor-blocking agents and
leflunomide for treating rheumatoid arthritis in the Netherlands.
Arthritis Rheum (Athritis Care & Research) 51:964–973
32. Emery P (2004) Review of health economics modelling in
rheumatoid arthritis. Pharmacoeconomics 22:55–69
33. Bansback N, Regier D, Ara R, Brennan A, Shojania K, Esdaile J,
Anis Aslam H, Marra Carlo A (2005) An overview of economic
evaluations for drugs used in rheumatoid arthritis: focus on
tumour necrosis factor-alpha antagonists. Drugs 65:473–496
34. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D,
Drummond M, Wong J, Gabriel S, Group obotOER (2003)
Economic evaluation of programs or interventions in the
management of rheumatoid arthritis: defining a reference case. J
Rheumatol 30:891–896
35. Wells G, Boers M, Shea B, Brooks P, Simon L, Strand C, Aletaha
D, Anderson J, Bombardier C, Dougados M, Emery P, Felson D,
Fransen J, Furst D, Hazes J, Johnson K, Kirwan J, Landewé R,
Lassere M, Michaud K, Suarez-Almazor M, Silman A, Smolen J,
Van der Heijde D, van Riel P, Wolfe F, Tugwell P (2005) Minimal
disease activity for rheumatoid arthritis: a preliminary definition. J
Rheumatol 32:2016–2024
36. Lyseng-Williamson KA, Plosker GL (2004) Etanercept: a phar-
macoeconmic review of its use in rheumatoid arthritis. Pharma-
coeconomics 22:1071–1095
37. Doan QV, Chiou CG, Dubois RW (2006) Review of eight
pharmacoeconomic studies of the value of biologic DMARDS
(adalimumab, etanercept and infliximab) in the management of
rheumatoid arthritis. J Manag Care Pharm 12:555–569
38. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson
K, Symmons D (2007) Modelling the cost-effectiveness of TNF-
alpha antagonists in the management of rheumatoid arthritis:
results from the British Society for Rheumatology Biologics
Registry. Rheumatology 46:1345–1354
39. Suarez-Almazor M, Conner-Spady B (2001) Rating of arthritis
health states by patients, physicians, and the general public.
Implications for cost-utility analyses. J Rheumatol 28:648–656
40. Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyan-
nis N (2002) Limitations of the methods used for calculating
quality-adjusted life-year values. Pharmacoeconomics 20:463–473
41. Mc Gregor M, Caro J (2006) QALYs: Are they helpful to decision
makers? Pharmacoeconomics 24:947–952
42. Jorstad I, Kirstiansen I, Uhlig T et al (2005) Performance of four
utility measures in 1041 patients with rheumatoid arthritis (RA):
Clin Rheumatol (2009) 28:403–412 411
well correlated but differing widely in valuing health states.
Arthritis Rheum 52:S660
43. Ariza-Ariza R, Hernández-Cruz B, Carmona L, Ruiz-Montecinos
MD, Ballina J, Navarro-Sarabia F, Group CaQoLiRAS (2006)
Assessing utility values in rheumatoid arthritis: a comparison
between time trade-off and the EuroQol. Arthritis Rheum
(Arthritis Care Res) 55:751–756
44. Beresniak A, Russell A, Haraoui B, Bessette L, Bombardier C,
Duru G (2007) Advantages and limitations of utility assessment
methods in rheumatoid arthritis. J Rheumatol 34:2193–2200
45. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-
Arboleya L, Navarro-Compán V, Toyos J (2007) Dose escalation
of the anti-TNF-α agents in patients with rheumatoid arthritis. A
systematic review. Rheumatology 46:529–532
46. Haraoui B, Cameron L, Ouellet M, White B (2006) Anti-
infliximab antibodies in patients with rheumatoid arthritis who
require higher doses of infliximab to achieve or maintain a clinical
response. J Rheumatol 33:31–36
47. Wolbink G, Vis M, Lems W, Voskuyl A, de Groot E,
Nurmohamed M, Stapel S, Tak P, Aarden L, Dijkmans B (2006)
Development of antiinfliximab antibodies and relationship to
clinical response in patients with rheumatoid arthritis. Arthritis
Rheum 54:711–715
48. Berger A, Edelsberg J, Li T, Maclean J, Oster G (2005) Dose
intensification with infliximab in patients with rheumatoid
arthritis. Ann Pharmacother 39:2021–2025
49. Stern R, Wolfe F (2004) Infliximab dose and clinical status:
results of 2 studies in 1642 patients with rheumatoid arthritis. J
Rheumatol 31:1538–1545
50. Fitzcharles M, Clayton D, Menard H (2002) The use of infliximab
in academic rheumatology practice: an audit of early clinical
experience. J Rheumatol 29:2525–2530
51. Agarwal S, Maier A, Chibnik L, Coblyn J, Fossel A, Lee R,
Fanikos J, Fiumara K, Lowry C, Weinblatt M (2005) Pattern of
infliximab utilization in rheumatoid arthritis patients at an academic
medical center. Arthritis Rheum (Arthritis Care Res) 53:872–878
412 Clin Rheumatol (2009) 28:403–412
